Loading the company…
Loading the company…
㈜푸르고바이오로직스
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-09 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Gyeonggi, founded in 2003. Industry: Bio & Pharma. Revenue for 2025 was ₩23.7bn. It has 59 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2019-06-07 · latest registration 2020-05-21 · newest first
홀이 형성된 골 이식재 제조방법이 개시된다. 본 발명의 일 실시 예에 따른 홀이 형성된 골 이식재 제조방법은, 생분해성 고분자를 마련하는 생분해성 고분자 마련단계; 생분해성 고분자에 골재료를 혼합한 성형재료를 마련하는 성형재료 마련단계; 성형재료를 홀(hole)이 형성된 골 이식재로 성형하기 위한 홀 성형 몰드(mold)에 투입하는 성형재료 투입단계; 및 홀 성형 몰드에 투입된 성형재료를 미리 결정된 온도에서 건조시킴으로써 홀이 형성된 골 이식재로 성형하는 홀이 형성된 골 이식재 성형단계를 포함한다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 22.7 | 23.7 |
| Cost of sales | 8.0 | 8.2 |
| Gross profit (loss) | 14.7 | 15.5 |
| Selling, general and administrative expenses | 11.2 | 11.8 |
| Operating income (loss) | 3.5 | 3.8 |
| Non-operating income | 0.6 | 0.3 |
| Other gains | 0.1 | 0.0 |
| Finance income | 0.0 | 0.0 |
| Other | 0.5 | 0.2 |
| Non-operating expenses | 0.2 | 0.5 |
| Other losses | 0.0 | 0.2 |
| Finance costs | 0.1 | 0.1 |
| Other | 0.1 | 0.3 |
| Profit (loss) before tax | 4.0 | 3.5 |
| Income tax expense | 0.1 | 0.2 |
| Net income (loss) | 3.8 | 3.2 |
Revenue ₩23.7bn, up 4.4% YoY.
Operating margin 15.9% (prior 15.5%).
Net income ₩3.2bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06